✦ LIBER ✦

Interferon therapy in chronic myelogenous leukemia

✍ Scribed by Guilhot, François; Roy, Lydia; Guilhot, Joëlle; Millot, Fredéric

Book ID: 122015643
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 284 KB
Volume: 18
Category: Article
ISSN: 0889-8588
DOI: 10.1016/j.hoc.2004.03.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Initial expression of interferon alpha r

Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia

✍ Kinro Ito; Hideo Tanaka; Takuo Ito; Tanvira A. Sultana; Taiichi Kyo; Fumio Imana 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB

Effect of interferon-alpha therapy on bo

Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia

✍ Wilhelm, M; Bueso-Ramos, C; O’Brien, S; Pierce, S; Keating, M; Talpaz, M; Kantar 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 541 KB

Combination therapy with interferon-alph

Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia

✍ Eleftheria Chr Hatzimichael; Konstantinos L Bourantas 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Emergence of Unusual Cytogenetic Abnorma

Emergence of Unusual Cytogenetic Abnormalities under Interferon-Alpha Therapy in Patients with Chronic Myelogenous Leukemia

✍ Frédéric Maloisel; Françoise Uettwiller; Anne Laplace; Bruno Lioure; Raoul Herbr 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Down-regulation of peripheral blood cell

Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFNα) therapy

✍ Beth Lynn Maxwell; Moshe Talpaz; Jordan U. Gutterman 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 French ⚖ 608 KB

## Abstract Our interest in studying interferon (IFN) receptor activity in peripheral blood cells (PBCs) from patients with chronic myelogenous leukemia (CML) receiving therapeutic doses of partially purified leukocyte IFN (IFNα) stems from a need for more adequate monitoring of IFN therapy. The bi

A phase II study alternating alpha-2a-in

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

✍ M. Talpaz; R. Kurzrock; H. Kantarjian; J. Rothberg; S. Saks; L. Evans; J. U. Gut 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB